Literature DB >> 18991713

Monitoring of treatment-induced apoptosis in oncology with PET and SPECT.

Francis G Blankenberg1.   

Abstract

The early assessment of a solid tumor's response to conventional or new drug therapy to complement or replace current RECIST (or other clinical) criteria remains an elusive goal. The work horse PET tracer (18)F-FDG, may represent the most immediate method to track individual tumor response to therapy for many types of cancer. Newer radiotracers such as radiolabeled annexin V, have also shown the ability to selectively localize to tumor cells undergoing apoptosis (programmed cell death) in response to successful treatment in vivo. In this article we will review therapy reduced tumor apoptosis and the radiotracers used to date to image this process in both animal models and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991713     DOI: 10.2174/138161208786404353

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

Review 1.  Visualizing cell death in experimental focal cerebral ischemia: promises, problems, and perspectives.

Authors:  Marietta Zille; Tracy D Farr; Ingo Przesdzing; Jochen Müller; Clemens Sommer; Ulrich Dirnagl; Andreas Wunder
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-16       Impact factor: 6.200

Review 2.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

3.  In vivo targeting of cell death using a synthetic fluorescent molecular probe.

Authors:  Bryan A Smith; Shuzhang Xiao; William Wolter; James Wheeler; Mark A Suckow; Bradley D Smith
Journal:  Apoptosis       Date:  2011-07       Impact factor: 4.677

Review 4.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

Review 5.  New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.

Authors:  Graham Smith; Laurence Carroll; Eric O Aboagye
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

6.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

7.  [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].

Authors:  N Schramm; M Schlemmer; C Rist; R Issels; M F Reiser; F Berger
Journal:  Radiologe       Date:  2010-04       Impact factor: 0.635

8.  Synthesis of ApoSense compound [18F]2-(5-(dimethylamino)naphthalene-1-sulfonamido)-2-(fluoromethyl)butanoic acid ([18F]NST732) by nucleophilic ring opening of an aziridine precursor.

Authors:  Falguni Basuli; Haitao Wu; Zhen-Dan Shi; Bao Teng; Changhui Li; Agnieszka Sulima; Aaron Bate; Philip Young; Mathew McMillan; Gary L Griffiths
Journal:  Nucl Med Biol       Date:  2012-02-14       Impact factor: 2.408

9.  Tumor necrosis in osteosarcoma: inclusion of the point of greatest metabolic activity from F-18 FDG PET/CT in the histopathologic analysis.

Authors:  Colleen M Costelloe; A Kevin Raymond; Nancy E Fitzgerald; Osama R Mawlawi; Rodolfo F Nunez; John E Madewell; Robyn K Harrell; Roland L Bassett; Edith M Marom
Journal:  Skeletal Radiol       Date:  2009-09-17       Impact factor: 2.199

Review 10.  Molecular probes for the in vivo imaging of cancer.

Authors:  Raphael Alford; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Biosyst       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.